Frequent Detection of Pancreatic Lesions in Asymptomatic High-risk Individuals
Overview
Authors
Affiliations
Background & Aims: The risk of pancreatic cancer is increased in patients with a strong family history of pancreatic cancer or a predisposing germline mutation. Screening can detect curable, noninvasive pancreatic neoplasms, but the optimal imaging approach is not known. We determined the baseline prevalence and characteristics of pancreatic abnormalities using 3 imaging tests to screen asymptomatic, high-risk individuals (HRIs).
Methods: We screened 225 asymptomatic adult HRIs at 5 academic US medical centers once, using computed tomography (CT), magnetic resonance imaging (MRI), and endoscopic ultrasonography (EUS). We compared results in a blinded, independent fashion.
Results: Ninety-two of 216 HRIs (42%) were found to have at least 1 pancreatic mass (84 cystic, 3 solid) or a dilated pancreatic duct (n = 5) by any of the imaging modalities. Fifty-one of the 84 HRIs with a cyst (60.7%) had multiple lesions, typically small (mean, 0.55 cm; range, 2-39 mm), in multiple locations. The prevalence of pancreatic lesions increased with age; they were detected in 14% of subjects younger than 50 years old, 34% of subjects 50-59 years old, and 53% of subjects 60-69 years old (P < .0001). CT, MRI, and EUS detected a pancreatic abnormality in 11%, 33.3%, and 42.6% of the HRIs, respectively. Among these abnormalities, proven or suspected neoplasms were identified in 85 HRIs (82 intraductal papillary mucinous neoplasms and 3 pancreatic endocrine tumors). Three of 5 HRIs who underwent pancreatic resection had high-grade dysplasia in less than 3 cm intraductal papillary mucinous neoplasms and in multiple intraepithelial neoplasias.
Conclusions: Screening of asymptomatic HRIs frequently detects small pancreatic cysts, including curable, noninvasive high-grade neoplasms. EUS and MRI detect pancreatic lesions better than CT.
Pancreatic cancer: Future challenges and new perspectives for an early diagnosis.
Cocca S, Pontillo G, Lupo M, Lieto R, Marocchi M, Marsico M World J Clin Oncol. 2025; 16(2):97248.
PMID: 39995556 PMC: 11686566. DOI: 10.5306/wjco.v16.i2.97248.
Current Approaches of Pancreatic Cancer Surveillance in High-Risk Individuals.
Heller M, Mann D, Katona B J Gastrointest Cancer. 2025; 56(1):61.
PMID: 39932614 PMC: 11814005. DOI: 10.1007/s12029-025-01184-1.
Advances in Endoscopic Ultrasound in Pancreatic Cancer Screening, Diagnosis, and Palliative Care.
Zhang W, Chen J, Zhang W, Xu M Biomedicines. 2025; 13(1).
PMID: 39857661 PMC: 11762820. DOI: 10.3390/biomedicines13010076.
Nonaka K, Arakawa A, Hara M, Komatsu A, Nagasaka T, Kumasaka T Cureus. 2024; 16(9):e70225.
PMID: 39463607 PMC: 11512164. DOI: 10.7759/cureus.70225.
Inactivation of HIPK2 attenuates KRAS activity and prevents pancreatic tumorigenesis.
Sozzi S, Manni I, Ercolani C, Diodoro M, Bartolazzi A, Spallotta F J Exp Clin Cancer Res. 2024; 43(1):265.
PMID: 39342278 PMC: 11437985. DOI: 10.1186/s13046-024-03189-3.